Advanced Biomedical Research
EPCAM Expression in Colon Adenocarcinoma and its Relationship with TNM Staging
Document Type : Original Article
Authors
Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Since epithelial cell adhesion molecule glycoprotein (EPCAM) is associated with the development and metastasis of colon adenocarcinoma, it can be helpful in predicting the tumor stage before surgery. In this study, we investigated EPCAM glycoprotein expression in colon adenocarcinoma and its relationship with tumor staging. Materials and Methods: This study was done on formalin-fixed and paraffin-embedded tissues of 71 patients diagnosed with colon adenocarcinoma, together with normal tissues around them, which were available at the archive of pathology lab of Al-Zahra hospital, Isfahan. Hematoxylin and eosin (HandE) and immunohistochemistry (IHC) staining methods for EPCAM marker were performed on paraffin-embedded blocks. Results: The percentage of staining of EPCAM glycoprotein in the tumoral and normal tissues of 71 patients with colon adenocarcinoma was studied and compared. In normal tissue, 84.5% showed strong staining, 15.5% showed moderate to strong, and none of the patients showed moderate, weak, or no staining at all. In the tumoral tissue, 25.4% had strong, 25.4% had moderate to strong, 26.8% showed moderate, 16.9% showed weak and 5.6% had no staining at all. EPCAM expression was significantly less in tumoral tissue than in normal. Conclusion: There was an inverse relationship between tumor staging and the percentage of staining in EPCAM glycoprotein so this marker can be used for predicting the tumor stage.
Keywords
| 1. |
Malekzadeh R, Bishehsari F, Mahdavinia M, Ansari R. Epidemiology and molecular Genetics of Colorectal Cancer in Iran: A Review. Arch Iran Med 2009;12:161-9.  |
| 2. |
Rosai J. Rosai and Ackerman's surgical pathology. New York, NY, USA: Elsevier; 2011. p. 768-9. |
| 3. |
Songun I, Litvinov SV, Vandevelde C, Vals S, Hermans J. Loss of EPCAM (CD 17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005;92:1767-72. |
| 4. |
Shiah SH-G, Tai K-Y, Wu CH-W. Epigenic regulation of EPCAM in tumor invasion and metastasis. J Cancer Moecules 2008;3:165-8. |
| 5. |
Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC. EPCAM an immunotherapeutic target for gastrointestinal malignancy: Current experience and future challenges. Br J Cancer 2007;96:1013-9. |
| 6. |
Bauerle P. EPCAM as a target in cancer therapy. J Clin Oncol 2010;28:239-40. |
| 7. |
Went PT, Luqli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EPCAM protein expression in human carcinoma. Hum Pathol 2004;35:122-8. |
| 8. |
Baurele P, Ruettinger D. EPCAM's Renaissance. Drug Discovery and Development 2009 April. |
| 9. |
Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Reide V, et al. Frequent high-level expression of the immunotherapeutic target EPCAM in colon, stomach, prostate and lung cancer. Br J Cancer 2006;94:128-35. |
| 10. |
Kuhn S, Koch M, Nübel T, Ladwein M, Antolovic D, Klingbeil P, et al. A complex of EPCAM, claudin-7, CD44 variant isoforms and Tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007;5:553-67. |
| 11. |
Spizzo G, Fong D, Wurn M, Ensinger CH, Obrist P, Hofer C, et al. EPCAM expression in primary tumor tissue and metastases: An immunohistochemical analysis. J Clin Pathol 2011;64:415-20.
|
)